Related Experiment Video

Updated: Apr 30, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

300

Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 status

Lisa Lange1, Sarah Keppner-Witter, Juline Grigat

  • 1Friedrich-Schiller-University, CMB, Institute for Biochemistry, Hans-Knöll-Straße 2, 07745 Jena, Germany.

Oncotarget
|May 10, 2014
PubMed

Insights

Combining Enzastaurin (targeting PKCβ) and SBE13 (targeting Plk1) shows synergistic effects in p53-deficient cancer cells. This combination is a promising strategy for treating cancers lacking functional p53.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Protein kinase C beta (PKCβ) and Polo-like kinase 1 (Plk1) are validated targets in cancer therapy.
  • Combinatorial targeting strategies are being explored to enhance treatment efficacy.

Purpose of the Study:

  • To investigate the synergistic effects of combined PKCβ and Plk1 inhibition in cancer cells with varying p53 functional status.
  • To determine the role of p53 in mediating cellular responses to dual inhibition of PKCβ and Plk1.

Main Methods:

  • Utilized Enzastaurin (PKCβ inhibitor) and SBE13 (Plk1 inhibitor) in cancer cell lines (HeLa, MCF-7, HCT116 with wild-type and deficient p53) and normal cells (hTERT-RPE1).
  • Assessed cell proliferation, apoptosis, cell cycle distribution via Western blot and FACScan analyses.
  • Correlated treatment effects with p53 status and cell cycle checkpoint function.

Main Results:

  • p53-deficient cancer cells exhibited synergistic proliferation reduction and S/G2/M phase enrichment upon combined treatment.
  • p53-wild-type cancer cells and normal cells showed resistance, with G0/G1 phase arrest, indicating p53-dependent protection.
  • Plk1 inhibition by SBE13 potentiated Enzastaurin's effects, confirming synergy.

Conclusions:

  • The combination of Enzastaurin and SBE13 demonstrates p53-dependent synergistic cytotoxicity in cancer cells.
  • p53 acts as a protective factor against this combined therapeutic approach.
  • This drug combination holds potential for selectively targeting p53-deficient cancers while sparing normal tissues.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K
Yeast As a Chassis for Developing Functional Assays to Study Human P5314:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

8.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
32.1K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
8.5K